Carsten Saft

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4303052/publications.pdf

Version: 2024-02-01

71 papers	1,727 citations	257357 24 h-index	302012 39 g-index
75 all docs	75 docs citations	75 times ranked	2392 citing authors

#	Article	IF	Citations
1	Transcript-Specific Loss-of-Function Variants in VPS16 Are Enriched in Patients With Dystonia. Neurology: Genetics, 2022, 8, e644.	0.9	9
2	No optical coherence tomography changes in premanifest Huntington's disease mutation carriers far from disease onset. Brain and Behavior, 2022, 12, e2592.	1.0	5
3	Divergent Effects of the Nonselective Adenosine Receptor Antagonist Caffeine in Pre-Manifest and Motor-Manifest Huntingtonâ€™s Disease. Biomedicines, 2022, 10, 1258.	1.4	1
4	Resurrection of sildenafil: potential for Huntingtonâ€™s Disease, too?. Journal of Neurology, 2022, 269, 5144-5150.	1.8	1
5	Altered thirdâ€party punishment in Huntington's disease: A study using neuroeconomic games. Brain and Behavior, 2021, 11, e01908.	1.0	9
6	Correspondence on â€œClinical, neuropathological, and genetic characterization of STUB1 variants in cerebellar ataxias: a frequent cause of predominant cognitive impairmentâ€•by Roux et al.. Genetics in Medicine, 2021, 23, 1171-1172.	1.1	2
7	Association of CAG Repeat Length in the Huntington Gene With Cognitive Performance in Young Adults. Neurology, 2021, 96, e2407-e2413.	1.5	12
8	Longitudinal Evaluation of the Effect of Tricyclic Antidepressants and Neuroleptics on the Course of Huntingtonâ€™s Diseaseâ€”Data from a Real World Cohort. Brain Sciences, 2021, 11, 413.	1.1	10
9	Teaching Video NeuroImages: New STUB1 Variant Causes Chorea, Tremor, Dystonia, Myoclonus, Ataxia, Depression, Cognitive Impairment, Epilepsy, and Superficial Siderosis. Neurology, 2021, 97, 10.1212/WNL.0000000000012264.	1.5	4
10	Differential Diagnosis of Choreaâ€”HIV Infection Delays Diagnosis of Huntingtonâ€™s Disease by Years. Brain Sciences, 2021, 11, 710.	1.1	4
11	Tit for Tat: Costly Punishment in Manifest Huntingtonâ€™s Disease. Neurodegenerative Diseases, 2021, 21, 74-78.	0.8	1
12	Another Perspective on Huntingtonâ€™s Disease: Disease Burden in Family Members and Pre-Manifest HD When Compared to Genotype-Negative Participants from ENROLL-HD. Brain Sciences, 2021, 11, 1621.	1.1	10
13	Emergence of Bruxism after Reducing Left Pallidal Stimulation in a Patient with Huntington's Disease. Movement Disorders Clinical Practice, 2020, 7, 704-705.	0.8	3
14	Time will tell: Decision making in premanifest and manifest Huntingtonâ€™s disease. Brain and Behavior, 2020, 10, e01843.	1.0	9
15	Patterns of CAG repeat instability in the central nervous system and periphery in Huntingtonâ€™s disease and in spinocerebellar ataxia type 1. Human Molecular Genetics, 2020, 29, 2551-2567.	1.4	69
16	Functional and cognitive capacity differ in dystonic motor subtypes when compared to choreatic and hypokineticâ€rigid motor subtypes in Huntington's disease. Brain and Behavior, 2020, 10, e01704.	1.0	8
17	Clinical Manifestation of Juvenile and Pediatric HD Patients: A Retrospective Case Series. Brain Sciences, 2020, 10, 340.	1.1	19
18	Antiepileptic effects of cobalt, manganese and magnesium on bicuculline-induced epileptiform activity in hippocampal neurons. Brain Research, 2020, 1732, 146684.	1.1	2

#	Article	IF	Citations
19	Obsessive-Compulsive Symptoms are Less Common in Huntingtonâ€™s Disease than Reported Earlier. Journal of Huntington's Disease, 2019, 8, 493-500.	0.9	3
20	A protein quality control pathway regulated by linear ubiquitination. EMBO Journal, 2019, 38, .	3.5	63
21	Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease?. Movement Disorders, 2019, 34, 584-585.	2.2	16
22	Objective assessment of gait and posture in premanifest and manifest Huntington disease â€" A multi-center study. Gait and Posture, 2018, 62, 451-457.	0.6	18
23	Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease. Experimental Neurology, 2018, 302, 112-128.	2.0	20
24	Pallidal deep brain stimulation in juvenile Huntington's disease: local field potential oscillations and clinical data. Journal of Neurology, 2018, 265, 1573-1579.	1.8	11
25	Cannabinoids for Treatment of Dystonia in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2018, 7, 167-173.	0.9	33
26	Does arterial hypertension influence the onset of Huntington's disease?. PLoS ONE, 2018, 13, e0197975.	1.1	6
27	J01â€...Effects of IONIS-HTTRX (RG6042) in patients with early huntingtonâ€™s disease, results of the first htt-lowering drug trial. , 2018, , .		2
28	P 329. Patients with Juvenile Huntingtonâ€™s Disease Benefit from Early Diagnosis. Neuropediatrics, 2018, 49, .	0.3	0
29	Progressive spinal cord atrophy in manifest and premanifest Huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 614-616.	0.9	5
30	Identifying modifiers of Huntington's disease progression. Lancet Neurology, The, 2017, 16, 679-680.	4.9	0
31	Laquinimod treatment in the R6/2 mouse model. Scientific Reports, 2017, 7, 4947.	1.6	36
32	L22â€...Intranasal application of NPY and NPY13â€“36 ameliorate disease pathology in R6/2 mouse model of huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A97.2-A98.	0.9	1
33	Two different phenomena in basic motor speech performance in premanifest Huntington disease. Neurology, 2016, 87, 2283-2283.	1.5	1
34	Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease. Experimental Neurology, 2016, 285, 12-23.	2.0	28
35	L7â€...Laquinimod in the R6/2 mouse model of huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A92.2-A92.	0.9	0
36	E2â€...Progression of motor subtypes in huntingtonâ€™s disease: a six-year follow-up study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A45.2-A45.	0.9	0

#	Article	IF	Citations
37	Two different phenomena in basic motor speech performance in premanifest Huntington disease. Neurology, 2016, 86, 1329-1335.	1.5	23
38	A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntingtonâ€™s Disease. Frontiers in Neurology, 2015, 6, 177.	1.1	47
39	Echogenicity of basal ganglia structures in different Huntingtonâ€™s disease phenotypes. Journal of Neural Transmission, 2015, 122, 825-833.	1.4	7
40	Treating the whole body in Huntington's disease. Lancet Neurology, The, 2015, 14, 1135-1142.	4.9	126
41	Exploring Genetic Factors Involved in Huntington Disease Age of Onset: E2F2 as a New Potential Modifier Gene. PLoS ONE, 2015, 10, e0131573.	1.1	11
42	High noon back pain- severe pseudoradicular pain as a lead symptom of superficial siderosis: a case report. Therapeutic Advances in Neurological Disorders, 2014, 7, 276-278.	1.5	1
43	Progressive hepatic mitochondrial dysfunction in premanifest Huntington's disease. Movement Disorders, 2014, 29, 831-834.	2.2	27
44	Cross sectional PET study of cerebral adenosine A1 receptors in premanifest and manifest Huntingtonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1210-1220.	3.3	34
45	Clinical utility gene card for: Huntingtonâ€™s disease. European Journal of Human Genetics, 2014, 22, 713-713.	1.4	4
46	What is the course of Huntington's disease?. Lancet Neurology, The, 2014, 13, 1165-1166.	4.9	4
47	Impaired motor speech performance in Huntingtonâ€™s disease. Journal of Neural Transmission, 2014, 121, 399-407.	1.4	48
48	Benign hereditary chorea as an experimental model to investigate the role of medium spiny neurons for response adaptation. Neuropsychologia, 2014, 59, 124-129.	0.7	5
49	Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation. Experimental Neurology, 2014, 257, 50-56.	2.0	25
50	Mentalizing in preclinical Huntingtonâ€™s disease: an fMRI study using cartoon picture stories. Brain Imaging and Behavior, 2013, 7, 154-162.	1.1	16
51	Oral and dental health in Huntingtonâ€˜s disease - an observational study. BMC Neurology, 2013, 13, 114.	0.8	11
52	Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease. Neurology, 2013, 80, 743-746.	1.5	52
53	Better global and cognitive functioning in choreatic versus hypokineticâ€rigid Huntington's disease. Movement Disorders, 2013, 28, 1142-1145.	2.2	29
54	Diadochokinetic movements differ between patients with Huntington's disease and controls. NeuroRehabilitation, 2013, 33, 649-655.	0.5	3

#	Article	IF	Citations
55	Depression in patients with Huntington disease correlates with alterations of the brain stem raphe depicted by transcranial sonography. Journal of Psychiatry and Neuroscience, 2011, 36, 187-194.	1.4	51
56	Post pump chorea in a 77-year-old male. Neurological Sciences, 2011, 32, 699-701.	0.9	10
57	Hepatic mitochondrial dysfunction in Friedreich Ataxia. BMC Neurology, 2011, 11, 145.	0.8	15
58	PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease. Molecular Neurodegeneration, 2011, 6, 32.	4.4	106
59	No evidence of impaired gastric emptying in early Huntingtonâ€˜s Disease. PLOS Currents, 2011, 3, RRN1284.	1.4	4
60	Mitochondrial haplogroup H correlates with ATP levels and age at onset in Huntington disease. Journal of Molecular Medicine, 2010, 88, 431-436.	1.7	56
61	Upper gastrointestinal findings in Huntingtonâ€™s disease: patients suffer but do not complain. Journal of Neural Transmission, 2009, 116, 1607-1611.	1.4	58
62	Huntington's disease as caused by 34 CAG repeats. Movement Disorders, 2008, 23, 879-881.	2.2	46
63	fMRI reveals altered auditory processing in manifest and premanifest Huntington's disease. Neuropsychologia, 2008, 46, 1279-1289.	0.7	64
64	Functional Connectivity During Auditory Processing in Huntingtonâ€™s Disease. Journal of Psychophysiology, 2008, 22, 195-201.	0.3	0
65	Time Processing in Huntington's Disease: A Group-Control Study. PLoS ONE, 2007, 2, e1263.	1.1	65
66	NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Human Genetics, 2007, 122, 175-182.	1.8	64
67	Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series. BMC Neurology, 2006, 6, 11.	0.8	55
68	Assessment of simple movements reflects impairment in Huntington's disease. Movement Disorders, 2006, 21, 1208-1212.	2.2	33
69	Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Movement Disorders, 2005, 20, 674-679.	2.2	162
70	Supracubital perineurioma misdiagnosed as carpal tunnel syndrome: case report. BMC Neurology, 2004, 4, 19.	0.8	4
71	Assessment of complex movements reflects dysfunction in Huntington?s disease. Journal of Neurology, 2003, 250, 1469-1474.	1.8	29